Sentencing for Criminals Now Tops 625 Years

STONY BROOK N.Y., November 26, 2018 – Applied DNA Sciences Inc. (NASDAQ: APDN, “Applied DNA,” “the Company”), the leader in large-scale PCR-based DNA manufacturing, is pleased to report that SigNature DNA evidence has resulted in over 131 convictions, with sentences of 625 years to date, and many more cases in the pipeline.

The confirmed number of convictions and sentencing are received from law enforcement officers. Due to internal protocols in some European countries, we do not always receive confirmation of the outcome of criminal investigations; for that reason, we estimate the actual numbers to be significantly higher.

The crimes we help solve with the aid of our SigNature DNA products include attacks against armored car companies, whose activity is commonly known across Europe as “Cash-and-Valuables-in-Transit.” Other types of crimes whose conviction benefits from Applied DNA’s technology include theft of entire vehicles and their components, Automated Teller Machine (ATM) burglary, and theft of goods from businesses and private residences.

The longest-serving distributor of Applied DNA’s security products, SmartDNA Protection Nordic AB, recently won an award from Deloitte Sweden Technology Fast 50, who recognize the region’s fastest-growing technology companies.

Tony Benson, Managing Director EMEA, commented, “We are very active across Europe working with industry and Law Enforcement agencies to help the fight against crime using a well-known, fundamental security principle of ‘Detect, Deter, Defend’. The criminals involved range from low-level burglars to highly-organized and violent criminals with global distribution capabilities.”

One of the robberies in question was solved in part due to the discovery of dye-stained cash found in the criminal’s home. This dye contained a unique SigNature DNA tag which definitively connected the stained notes to the cash box that was stolen from unarmed security guards as they refilled cash machines.

Benson added, “Law Enforcement agencies are very satisfied with the high quality and speed of service we provide. We commit to a 10-day turnaround time from receipt of forensic samples to the issuance of an Expert Witness Report, and we always meet or exceed this commitment. For the last 3 years, our average turnaround time has been 7 days, which we believe is best-in-class by a country mile. We attribute this excellence to the professionalism and dedication of our Forensics team, led by Dr. Ila Lansky.

Dr. Lansky, Director of Forensics, added:  ”We recognize the importance of providing accurate and quick service to Law Enforcement agencies, who are often up against deadlines to release suspects on bail. In some countries, suspects skip bail on a regular basis. The Expert Witness Reports we produce and support in occasional court appearances are detailed, accurate, thoroughly documented and accepted by courts around the world. DNA evidence is often featured on “Crime Scene Investigation” programs, and therefore easily explained to the layperson, facilitating its use and strength in conviction.”

About Applied DNA Sciences
Applied DNA is a provider of molecular technologies that enable supply chain security, anti-counterfeiting and anti-theft technology, product genotyping and DNA mass production for diagnostics and therapeutics.

Applied DNA makes life real and safe by providing innovative, molecular-based technology solutions and services that can help protect products, brands, entire supply chains, and intellectual property of companies, governments and consumers from theft, counterfeiting, fraud and diversion.

Visit adnas.com for more information. Follow us on Twitter and LinkedIn. Join our mailing list.

The Company’s common stock is listed on NASDAQ under the symbol APDN, and its warrants are listed under the symbol APDNW.

Forward-Looking Statements
The statements made by Applied DNA in this press release may be “forward-looking” in nature within the meaning of the Private Securities Litigation Act of 1995. Forward-looking statements describe Applied DNA’s future plans, projections, strategies and expectations, and are based on assumptions and involve a number of risks and uncertainties, many of which are beyond the control of Applied DNA. Actual results could differ materially from those projected due to our history of losses, limited financial resources, limited market acceptance, the uncertainties inherent in research and development, future clinical data and analysis, including whether any of Applied DNA’s product candidates will advance further in the preclinical research or clinical trial process, including receiving clearance from the U.S. Food and Drug Administration or equivalent foreign regulatory agencies to conduct clinical trials and whether and when, if at all, they will receive final approval from the U.S. FDA or equivalent foreign regulatory agencies, and various other factors detailed from time to time in Applied DNA’s SEC reports and filings, including our Annual Report on Form 10-K filed on December 28, 2017 and our subsequent quarterly reports on Form 10-Q filed on February 8, 2018, May 3, 2018 and August 13, 2018, which are available at www.sec.gov. APDN undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date hereof to reflect the occurrence of unanticipated events, unless otherwise required by law.

Investor contact: Sanjay M. Hurry, LHA Investor Relations, 212-838-3777, shurry@lhai.com
Media contact: Cheryl Schneider, DGI Comm, 212-825-3210, cschneider@dgicomm.com
Program contact: Tony Benson, 44 (0) 7552 429341, tony.benson@adnas.com

Applied DNA, a leader in large-scale PCR-based DNA manufacturing, has signed a collaboration agreement with Eurofins BLC to support commercial implementation of Applied DNA’s SigNature T-based leather traceability system. The signing of the agreement follows successful completion of the funded consortium research project with BLC as announced in May 2018.

“There is a strong need within the leather industry to provide a robust system of traceability for semi-processed and finished leather. This cost-effective application system provides a process for applying a unique molecular tag in a way that is impossible to counterfeit. Eurofins BLC looks forward to supporting our customers in their journey towards supply chain transparency and traceability,” Adam Hughes, managing director of Eurofins BLC leather technology said.

Brands and retailers sourcing leather for their products are a step closer to being more equipped to trace the raw material through their supply chains.

DNA tags may be an effective tool to authenticate denim. The tag maintains its integrity even after the rigors of bleaching and abrasion, according to a new study by Applied DNA Sciences and the Fashion Institute of Technology (FIT). DNA tags may soon undergo testing at a full manufacturing facility to verify the authenticity of a finished denim garment.

The study has been published in the AATCC Review, a publication of the American Association of Textile Chemists and Colours.

At the FIT labs in New York, denim swatches were treated with unique DNA molecular tags produced by Applied DNA, then subjected to stone and bleach washings. The samples were then analysed at Applied DNA’s laboratories in Stony Brook, where it was proven that the DNA tags remained intact and suitable for high quality forensic scale analysis. Based on the observed stability, DNA tags of this kind may soon be ready for testing at a full manufacturing facility to verify the authenticity of the finished denim garment.

“This technology will enable brands and manufacturers to track their fibres from the farm through to the finished product, allowing for a more transparent supply chain. Traceability can also help verify certain sustainability claims about commodities and products, helping ensure good practices and respect for people and the environment in supply chains,” Sean Cormier, FIT assistant professor, Textile Development and Manufacturing, said.

Agreement leverages BLC’s leather processing expertise and strong ties to the global leather industry

STONY BROOK N.Y., November 19, 2018 – Applied DNA Sciences Inc. (NASDAQ: APDN, “Applied DNA,” “the Company”), the leader in large-scale PCR-based DNA manufacturing, announced today the signing of a Collaboration Agreement (the “Agreement”) with Eurofins BLC Leather Technology Center LTD (“BLC”) to support the commercial implementation of Applied DNA’s SigNature^® T-based leather traceability system (the “System”). The signing of the Agreement follows the successful completion of the funded consortium research project with BLC as announced in May 2018.

Tony Benson, Applied DNA’s Managing Director with responsibility for Europe, Middle East and Africa (EMEA) commented, “We are thrilled to enter into this mutually beneficial relationship with BLC to advance the commercial implementation of our leather tagging system. BLC’s unparalleled knowledge in all aspects of leather processing, long-standing relationships with global brands, and its history of forward-thinking innovation makes them an ideal partner.”

Dr. James Hayward president and CEO of Applied DNA stated, “This agreement with BLC significantly enhances our position for the commercial implementation of our leather tagging system. We already have keen interest in the commercial adoption of our system from several project sponsors. We are targeting a defined goal of having 300,000,000 square feet of DNA-tagged leather under contract over the next five years. BLC’s knowledge in the industry and technical expertise will be invaluable to these efforts.”

Adam Hughes, Managing Director of Eurofins BLC Leather Technology stated, “There is a strong need within the leather industry to provide a robust system of traceability for semi-processed and finished leather. This cost-effective application system provides a process for applying a unique molecular tag in a way that is impossible to counterfeit. Eurofins BLC looks forward to supporting our customers in their journey towards supply chain transparency and traceability.”

About Eurofins | BLC Leather Technology Centre
BLC is a leading, leather and chemical testing, consulting, auditing and technology centre, established over 95 years ago.

As a laboratory exclusively dedicated to leather, footwear, chemical, and leather product testing, BLC has the technical pedigree to ensure fast and accurate solutions to technical, management or environmental leather problems.

Eurofins Scientific is an International group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agroscience and consumer products industries. It is a leading provider of analytical services with an international network of more than 400 laboratories across 44 countries. Through research and development, in-licensing and acquisitions, the Group draws on the latest developments in the biotechnology and analytical sciences field.

About Applied DNA Sciences
Applied DNA is a provider of molecular technologies that enable supply chain security, anti-counterfeiting and anti-theft technology, product genotyping and DNA mass production for diagnostics and therapeutics.

Applied DNA makes life real and safe by providing innovative, molecular-based technology solutions and services that can help protect products, brands, entire supply chains, and intellectual property of companies, governments and consumers from theft, counterfeiting, fraud and diversion.

Visit adnas.com for more information. Follow us on Twitter and LinkedIn. Join our mailing list.

The Company’s common stock is listed on NASDAQ under the symbol APDN, and its warrants are listed under the symbol APDNW.

Forward-Looking Statements
The statements made by Applied DNA in this press release may be “forward-looking” in nature within the meaning of the Private Securities Litigation Act of 1995. Forward-looking statements describe Applied DNA’s future plans, projections, strategies and expectations, and are based on assumptions and involve a number of risks and uncertainties, many of which are beyond the control of Applied DNA. Actual results could differ materially from those projected due to our history of losses, limited financial resources, limited market acceptance, the uncertainties inherent in research and development, future clinical data and analysis, including whether any of Applied DNA’s product candidates will advance further in the preclinical research or clinical trial process, including receiving clearance from the U.S. Food and Drug Administration or equivalent foreign regulatory agencies to conduct clinical trials and whether and when, if at all, they will receive final approval from the U.S. FDA or equivalent foreign regulatory agencies, and various other factors detailed from time to time in Applied DNA’s SEC reports and filings, including our Annual Report on Form 10-K filed on December 28, 2017 and our subsequent quarterly reports on Form 10-Q filed on February 8, 2018, May 3, 2018 and August 13, 2018, which are available at www.sec.gov. APDN undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date hereof to reflect the occurrence of unanticipated events, unless otherwise required by law.

Investor contact: Sanjay M. Hurry, LHA Investor Relations, 212-838-3777, shurry@lhai.com
Media contact: Angie Mathews, 781-639-4924, angie@cgprpublicrelations.com
Program contact: Tony Benson, 44 (0) 7552 429341, tony.benson@adnas.com

Results of a new study published in the September/October 2018 issue of the AATCC Review have confirmed that DNA molecular tagging is an effective tool to authenticate denim and maintains its integrity even after exposed to the rigours of bleaching and abrasion.

The study was conducted by Applied DNA Sciences Inc. (Applied DNA) and the Fashion Institute of Technology (FIT). It was published in the AATCC Review, a highly regarded publication of the American Association of Textile Chemists and Colors.

STONY BROOK – New York-based molecular technology company Applied DNA Sciences, along with the Fashion Institute of Technology (FIT), have said that unique DNA molecular tags can be used to authenticate denim, even after it has been subjected to the rigorous practices that are standard in the industry.

Leading manufacturer of home textiles GHCL has launched Cirkularity, a new brand of eight lines of bedding supporting the circular economy. These lines centre on “reduce, reuse and recycle”. Rekoop, the inspiration behind Cirkularity, is a brand of bedding products made from recycled plastic (rPET) and is the first bedding product to use Applied DNA Sciences’ CertainT platform. Rekoop bedding products will be available for sale in the US beginning first quarter 2019.

Large-Scale Production of Linear DNA Shows the Best Lot-To-Lot Reproducibility and Sequence Accuracy for Kits Targeting Autoimmunity and Infectious Diseases

STONY BROOK, NY. November  7, 2018 – Applied DNA Sciences Inc. (NASDAQ: APDN) (“Applied DNA”), the leader in large-scale PCR-based DNA manufacturing, announced today that LineaRx, Inc. (“LineaRx”  or the “Company”) has been providing linear DNA to Technogenetics (Shanghai Kehua Bio-Engineering Co., Ltd-KHB group) that produces and sells kits to detect autoimmunity and infectious diseases.

The purified, PCR-produced DNA is custom-made for Technogenetics and is used to prepare the basic component responsible for the diagnostic specificity of two kits: one kit is used for the determination of dsDNA autoantibodies and the other for an ANA (Anti-Nuclear Antibodies) Screen.

“During the kits’ development, the Technogenetics R&D laboratories tested several polynucleotides. Only the linear DNA from LineaRx demonstrated high lot-to-lot reproducibility and the correct sequence of the polynucleotide,” said Clara Pasini, R&D – Clinical Affairs Consultant at Technogenetics. “These attributes improve the efficiency of our quality control for incoming raw materials and improve the overall quality, accuracy and reproducibility of our products.”

The Technogenetics kits employing linear DNA, assist in the laboratory diagnosis of systemic rheumatic autoimmune diseases such as systemic lupus erythematosus (SLE), Sjögren’s Syndrome (SS), progressive systemic sclerosis (PSS), dermatomyositis/polymyositis (DM/PM) and/or mixed connective tissue disease (MCTD).

In particular, the anti-dsDNA antibodies have high diagnostic value as autoantibody markers in patients with SLE, and for this reason they are included in the SLE classification criteria of the American College of Rheumatology. ^[1] Their prevalence in SLE varies from 40 to 80% according to case study and assay method. Besides its diagnostic function, the anti-dsDNA assay can play an important role in monitoring the progression of SLE, especially in patients with lupus nephritis. This is closely associated with the pathogenetic role of the antibodies: exacerbation of SLE is preceded by a constant and progressive increase of the anti-dsDNA antibodies, followed by a sharp decline at the moment of clinical recrudescence, which is justified by glomerular deposition of high-avidity DNA/anti-dsDNA immune complexes. _^[2] For this reason, this assay is widely used in the diagnosis and monitoring of SLE.

The molecular diagnostics market is projected to reach USD 11.54 billion by 2023 from USD 7.10 billion in 2017 at a CAGR of 8.4%. (MarketsandMarkets.com; May 2018).

“DNA produced by LineaRx is used by a number of customers who have a diagnostic solution in the market. These customers use our linear DNA as a critical part of their assay or as positive control for device calibration,” said Brian Viscount, Director of Product Management at Applied DNA. “Last year we shipped multiple grams of our linear DNA to our diagnostic customers. Linear DNA enables our diagnostic customers to minimize Quality Control costs and to ensure product reliability and consistency across their customer base. We are actively marketing to expand this business through new account acquisition and increasing our value add to existing customers.”

1. M Hochberg. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997; 40: 1725.
2. AJG Swaak, R Smeenk. Detection of anti-dsDNA as a diagnostic tool: a prospective study in 441 non-systemic lupus erythematosus (SLE ) patients with anti-dsDNA antibody (anti-dsDNA). Am Rheum Dis 1985; 44: 245-51.

About Technogenetics
Technogenetics is an innovative company working in the immunodiagnostics and molecular genetics fields. Technogenetics acts as a point of reference in the medical and scientific communities, developing and providing efficient, effective, environmentally friendly diagnostic solutions and products to improve prevention, diagnosis and treatment of several diseases.

Thanks to its high and specific know-how in the IVD (in vitro diagnostics) field, Technogenetics has provided an increased boost to research activities and manufacturing capabilities.

Technogenetics operates in international markets with strong partners. Due to the cooperation with international partners and an internal sales force, Technogenetics is well-known and appreciated in the industry being focused to customer needs and able to propose innovative solutions and avant-garde products.

About LineaRx
LineaRx seeks to commercialize the biotherapeutic value of Applied DNA’s deep expertise and experience in the design, manufacture and chemical modification of DNA by large scale polymerase chain reaction (“PCR”). Linear DNA is a form of DNA distinct from the circular form of DNA most commonly produced in plasmids and grown in bacteria. Plasmids are extrachromosomal DNA found in bacteria and are associated with the genes for antibiotic resistance which are often exchanged between bacteria and consequentially, are seen by many to embody a serious threat to global health. In addition, many nucleic acid-based therapies also rely on viral vectors for efficient transfection and expression of plasmid DNA. These viral vectors carry additional nontrivial risks and are extremely time consuming and expensive to manufacture.

About Applied DNA Sciences
Applied DNA is a provider of molecular technologies that enable supply chain security, anti-counterfeiting and anti-theft technology, product genotyping and DNA mass production for diagnostics and therapeutics.

Applied DNA makes life real and safe by providing innovative, molecular-based technology solutions and services that can help protect products, brands, entire supply chains, and intellectual property of companies, governments and consumers from theft, counterfeiting, fraud and diversion.

Visit adnas.com for more information. Follow us on Twitter and LinkedIn. Join our mailing list.

The Company’s common stock is listed on NASDAQ under the symbol APDN, and its warrants are listed under the symbol APDNW.

Forward-Looking Statements
The statements made by Applied DNA in this press release may be “forward-looking” in nature within the meaning of the Private Securities Litigation Act of 1995. Forward-looking statements describe Applied DNA’s future plans, projections, strategies and expectations, and are based on assumptions and involve a number of risks and uncertainties, many of which are beyond the control of Applied DNA. Actual results could differ materially from those projected due to our history of losses, limited financial resources, limited market acceptance, the uncertainties inherent in research and development, future clinical data and analysis, including whether any of Applied DNA’s product candidates will advance further in the preclinical research or clinical trial process, including receiving clearance from the U.S. Food and Drug Administration or equivalent foreign regulatory agencies to conduct clinical trials and whether and when, if at all, they will receive final approval from the U.S. FDA or equivalent foreign regulatory agencies, and various other factors detailed from time to time in Applied DNA’s SEC reports and filings, including our Annual Report on Form 10-K filed on December 28, 2017 and our subsequent quarterly reports on Form 10-Q filed on February 8, 2018, May 3, 2018 and August 13, 2018, which are available at www.sec.gov. APDN undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date hereof to reflect the occurrence of unanticipated events, unless otherwise required by law.

investor contact: Sanjay M. Hurry, LHA Investor Relations, 212-838-3777, shurry@lhai.com
media contact: Cheryl Schneider, DGI Comm, 212-825-3210, cschneider@dgicomm.com
program contact: Brian Viscount, 631-240-8877, brian.viscount@adnas.com
web: www.adnas.com, linearxdna.com
twitter: @APDN, @LineaRxDNA